Floatz logo

Pembrolizumab

Solid Tumor, Unspecified, Adult

Shenzhen Ionova Life Sciences Co., Ltd.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Solid Tumor, Unspecified, Adult cohort.

Asset / SponsorPhaseRating
Tislelizumab
Hutchmed
Phase 1/2CCC
ad1208
Avelos Therapeutics Inc.
Phase 1/2CCC
Mpb-1734
MegaPro Biomedical Co. Ltd.
Phase 1/2CCC
Pyrotinib
Hutchmed
Phase 1/2CCC
rc48-adc
Hutchmed
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →